<- Back to digest

JSES - 2026-11-09 - Journal Article

Stemless Anatomic Total Shoulder Arthroplasty is Associated with Less Opioid Use at Initial Follow-up.

Krumm ZR, Denard PJ, Brockmeier SF, Petre D, Kissenberth M, Shah A, Lederman E, Werner BC

retrospective cohortLOE IIIn = 817 (366 short-stem, 451 stemless)10–14 day initial postoperative visit only

Topics

shoulder elbow
PMID: 43003379DOI: 10.1016/j.jse.2026.11.028View on PubMed ->

Key Takeaway

Stemless aTSA was associated with 27.6% lower relative risk of opioid use at 10–14 days postoperatively (35.4% vs 48.9%, RR 0.724) despite equivalent VAS pain scores compared to short-stem aTSA.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This multicenter retrospective cohort study compared postoperative pain and opioid use between short-stem and stemless aTSA at the 10–14 day follow-up visit. VAS pain scores did not differ between groups (p=0.838), but stemless implant use was independently associated with lower postoperative VAS on multivariable regression (p=0.015) and with significantly lower opioid use prevalence (35.4% vs 48.9%, p<0.001, RR 0.724). Male sex and older age were also independently associated with lower postoperative pain, while higher baseline VAS predicted worse postoperative pain.

Key Limitation

The study captures only a single 10–14 day timepoint with no data on total opioid quantity dispensed, refill rates beyond initial follow-up, or whether prescribing differences between surgeons drove the observed opioid use disparity.

Original Abstract

BACKGROUND

As the rates of total shoulder arthroplasty (TSA) rise, surgeons are tasked with the need to manage initial postoperative pain to facilitate outpatient surgeries and increase functional and patient reported outcomes while minimizing avoidable complications and revision. Of particular interest is the effect of anatomic TSA (aTSA) design on postoperative pain and opioid use, especially in light of the national effort to reduce opioid prescriptions following orthopedic surgery.

METHODS

A multi-center retrospective cohort study was performed on patients who underwent either short-stem or stemless aTSA between 2013 and 2023. Two cohorts were established and baseline data on demographics, preoperative Visual Analog Scale (VAS) pain, and preoperative opioid use were obtained. The primary endpoint of this study was the postoperative VAS pain at the initial (10-14 day) postoperative follow-up, with the reported opioid use and the need for opioid medication refill as secondary endpoints. Student's t-test was performed on continuous variables, and chi-square or Fisher's exact test was performed on categorical variables as appropriate. Multivariable linear regression was performed to determine predictors of postoperative VAS.

RESULTS

817 patients were included in this study; 366 patients in the short-stem cohort and 451 in the stemless cohort. No difference was observed between groups for the preoperative VAS pain (p=0.102), postoperative VAS pain (p=0.838), and change in VAS pain (p=0.117). The prevalence of opioid use was lower at the initial follow-up visit in the stemless cohort (35.4% vs 48.9% in short-stem, p<0.001). The relative risk for opioid use for the stemless group was 0.724 (95% CI, 0.610-0.858). A stemless implant (p=0.015),male sex (p=0.039), and age (p<0.001) were all independently associated with lower postoperative VAS pain, whereas baseline VAS pain was independently associated with increased postoperative VAS pain (p<0.001). Older age was independently associated with a smaller change in VAS pain (p<0.001).

CONCLUSION

Patients undergoing stemless aTSA may not demonstrate different postoperative pain scores at initial follow-up than patients undergoing short-stem aTSA; however, use of a stemless aTSA has a weak to moderate association with less opioid medication use at initial follow-up. Although there was no statistically significant difference in postoperative VAS pain scores, patients who underwent stemless aTSA used less opioid medication by their initial 10-14 day postoperative visit than their short-stemmed aTSA comparison cohort.

LEVEL OF EVIDENCE

Level III; Retrospective Cohort Comparison; Treatment Study.